Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

More news

Drug interactions and pharmacokinetics news selected from other sources

  • Better Late Than Never: Efavirenz Dose Optimization

    After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

    03 April 2014 | Treatment Action Group
  • Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

    The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

    31 March 2014 | Morbidity and Mortality Weekly Report
  • Malnutrition decreases effectiveness of HIV treatment in pregnant African women

    In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

    19 February 2014 | Eurekalert Medicine & Health
  • Victrelis (boceprevir) label changes update contraindications and drug interactions

    On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.

    23 January 2014 | FDA
  • Risk of Harmful Drug Interactions Rises With Age in HIV+ US Group

    Every 10 years of age independently raised chances that a person in a US HIV cohort would be prescribed an antiretroviral and a nonantiretroviral that should not be given together. One third of cohort members were prescribed medications with moderate or high evidence of a possible drug-drug interaction.

    26 November 2013 | International AIDS Society
  • Merck plans phase III study of once-daily raltegravir (Isentress)

    The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. 17, and Friday, Oct. 18, from 12:00 p.m. to 2:00 p.m. CET. Based on the results of this study and other data, Merck plans to initiate a Phase III clinical study on a once daily dosing regimen of ISENTRESS in early 2014, pending review by regulatory agencies. ISENTRESS is administered twice daily, in accordance with the approved Prescribing Information.

    16 October 2013 | Merck press release
  • European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Tybost(TM) (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.

    26 September 2013 | Gilead press release
  • Adding Blood Pressure Drug to Standard Antibiotics Speeds Up TB Treatment

    Study in mice shows verapamil enhances isoniazid plus rifampin antibiotic therapy.

    02 September 2013 | Johns Hopkins Medicine press release
  • Trials challenging HIV drug doses could usher in huge cost cuts

    When researchers say they are trying to do more with less in the fight against HIV, they mean it. At last month's International AIDS Society (IAS) conference in Kuala Lumpur, Malaysia, researchers presented preliminary results from a clinical trial that showed a lower dose of the commonly used antiretroviral drug efavirenz was just as effective as the approved higher dose and seemed to cause fewer side effects in study participants.

    07 August 2013 | Nature Medicine
  • Nanoparticles May Transport HIV Meds to the Brain

    Researchers have had early success in a method that might one day thwart the powerful blood-brain barrier and effectively deliver antiretrovirals to the brain.

    16 May 2013 | AIDSMeds
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.